These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31272081)

  • 1. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.
    Felder S; Jann H; Arsenic R; Denecke T; Prasad V; Knappe-Drzikova B; Maasberg S; Wiedenmann B; Pavel M; Pascher A; Pape UF
    Endocr Relat Cancer; 2019 Sep; 26(9):751-763. PubMed ID: 31272081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Establishment of risk model for predicting the progression within 1 year of patients with gastric neuroendocrine neoplasms and its value of prediction].
    Peng X; Zhang Y; Bao Y; Zhou L; Muo Z; Chen H; Zhi F; Liu S; Chen J; Chen Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1247-1251. PubMed ID: 27928794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.
    Karakuş E; Helvacı A; Ekinci O; Dursun A
    Turk J Gastroenterol; 2014 Feb; 25(1):81-7. PubMed ID: 24918137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent classifications systems for gastroenteropancreatic neuroendocrine tumors A single-center experience.
    Yagmur Y; Söğutcü N; Gümüş S
    Ann Ital Chir; 2020; 91():598-604. PubMed ID: 32989209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology - grading and staging of GEP-NETs.
    Capelli P; Fassan M; Scarpa A
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):705-17. PubMed ID: 23582914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Improved Prognostic Stratification With the New World Health Organization 2019 Classification: A Validation Study From a Single-Institution Retrospective Analysis.
    Hayes AR; Furnace M; Shah R; Rundell C; Muller G; Dehbi HM; Luong TV; Toumpanakis C; Caplin ME; Krell D; Thirlwell C; Mandair D
    Pancreas; 2021 Apr; 50(4):516-523. PubMed ID: 33939663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort.
    Lithgow K; Venkataraman H; Hughes S; Shah H; Kemp-Blake J; Vickrage S; Smith S; Humphries S; Elshafie M; Taniere P; Diaz-Cano S; Dasari BVM; Almond M; Ford S; Ayuk J; Shetty S; Shah T; Geh I
    Sci Rep; 2021 Sep; 11(1):17947. PubMed ID: 34504148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study.
    Panzuto F; Campana D; Massironi S; Faggiano A; Rinzivillo M; Lamberti G; Sciola V; Lahner E; Manuzzi L; Colao A; Annibale B
    Dig Liver Dis; 2019 Oct; 51(10):1456-1460. PubMed ID: 31175013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
    Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
    Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of advanced high grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature.
    Mohamed A; Trybula M; Asa SL; Halfdanarson TR; Sonbol MB
    Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39133180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors.
    Hauck L; Bitzer M; Malek N; Plentz RR
    Scand J Gastroenterol; 2016 Jan; 51(1):55-9. PubMed ID: 26137871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.